Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015 (2015), Article ID 864597, 6 pages
http://dx.doi.org/10.1155/2015/864597
Research Article

Qing Re Liang Xue Decoction Alleviates Hypercoagulability in Kawasaki Disease

1Department of Pediatrics, Beijing Children’s Hospital, Capital Medical University, Beijing 100045, China
2Research Department Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing 100045, China

Received 29 December 2014; Revised 7 March 2015; Accepted 14 March 2015

Academic Editor: Zhang Tan

Copyright © 2015 Jiao-yang Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. C. Burns and M. P. Glodé, “Kawasaki syndrome,” The Lancet, vol. 364, no. 9433, pp. 533–544, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. A. H. Rowley, “Kawasaki disease: novel insights into etiology and genetic susceptibility,” Annual Review of Medicine, vol. 62, pp. 69–77, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. J. S. Hui-Yuen, T. T. Duong, and R. S. M. Yeung, “TNF-α is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease,” The Journal of Immunology, vol. 176, no. 10, pp. 6294–6301, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Xue, K. Sun, W.-P. Xie et al., “Etanercept attenuates short-term cigarette-smoke-exposure-induced pulmonary arterial remodelling in rats by suppressing the activation of TNF-α/NF-κB signal and the activities of MMP-2 and MMP-9,” Pulmonary Pharmacology &Therapeutics, vol. 25, no. 3, pp. 208–215, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. C. J. Beltrán, L. E. Núñez, D. Díaz-Jiménez et al., “Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 16, no. 7, pp. 1097–1107, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Duan, J. Chen, F. Gong, and G. Shi, “The role of IL-33 in rheumatic diseases,” Clinical and Developmental Immunology, vol. 2013, Article ID 924363, 5 pages, 2013. View at Publisher · View at Google Scholar
  7. J. Schmitz, A. Owyang, E. Oldham et al., “IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines,” Immunity, vol. 23, no. 5, pp. 479–490, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Préfontaine, S. Lajoie-Kadoch, S. Foley et al., “Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells,” The Journal of Immunology, vol. 183, no. 8, pp. 5094–5103, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Haraldsen, J. Balogh, J. Pollheimer, J. Sponheim, and A. M. Küchler, “Interleukin-33—cytokine of dual function or novel alarmin?” Trends in Immunology, vol. 30, no. 5, pp. 227–233, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Galeotti, J. Bayry, I. Kone-Paut, and S. V. Kaveri, “Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin,” Autoimmunity Reviews, vol. 9, no. 6, pp. 441–448, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Ayusawa, T. Sonobe, S. Uemura et al., “Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition),” Pediatrics International, vol. 47, no. 2, pp. 232–234, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. J. W. Newburger, M. Takahashi, M. A. Gerber et al., “Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association,” Circulation, vol. 110, no. 17, pp. 2747–2771, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Zhang, H. Zhang, P. Xu, and R.-Y. Su, “Research progress of Tanshinone II A pharmacological activity,” Yi Yao Dao Bao, vol. 28, no. 10, pp. 1237–1239, 2008. View at Google Scholar
  14. B.-G. Zhang, T.-F. Cheng, and Q.-F. Liu, “Efficacy and modern clinical application of Qingying decoction,” Chinese Traditional Patent Medicine, vol. 31, no. 11, pp. 1741–1744, 2009. View at Google Scholar
  15. X. Tu, S. Nie, Y. Liao et al., “The IL-33-ST2L pathway is associated with coronary artery disease in a Chinese Han population,” The American Journal of Human Genetics, vol. 93, no. 4, pp. 652–660, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Xu, H.-R. Jiang, P. Kewin et al., “IL-33 exacerbates antigen-induced arthritis by activating mast cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 31, pp. 10913–10918, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Seltmann, T. Werfel, and M. Wittmann, “Evidence for a regulatory loop between IFN-γ and IL-33 in skin inflammation,” Experimental Dermatology, vol. 22, no. 2, pp. 102–107, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. I. S. Wood, B. Wang, and P. Trayhurn, “IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes,” Biochemical and Biophysical Research Communications, vol. 384, no. 1, pp. 105–109, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Palmer, D. Talabot-Ayer, C. Lamacchia et al., “Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis,” Arthritis and Rheumatism, vol. 60, no. 3, pp. 738–749, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Matsuyama, H. Okazaki, M. Hoshino et al., “Sustained elevation of interleukin-33 in sera and synovial fluids from patients with rheumatoid arthritis non-responsive to anti-tumor necrosis factor: possible association with persistent IL-1β signaling and a poor clinical response,” Rheumatology International, vol. 32, no. 5, pp. 1397–1401, 2012. View at Publisher · View at Google Scholar
  21. X.-J. Ma, H.-J. Yin, and K.-J. Chen, “Research progress of correlation between blood-stasis syndrome and inflammation,” Chinese Journal of Integrative Medicine, vol. 27, no. 7, pp. 669–672, 2007. View at Google Scholar · View at Scopus
  22. J. L. Wright, H. Tai, R. Wang, X. Wang, and A. Churg, “Cigarette smoke upregulates pulmonary vascular matrix metalloproteinases via TNF-α signaling,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 292, no. 1, pp. L125–L133, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Kuhota, C. F. McTiernan, C. S. Frye et al., “Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha,” Circulation Research, vol. 81, no. 4, pp. 627–635, 1997. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Xie, W. Wang, H.-H. Zhao, and S.-Z. Guo, “Relationgship between plasma ApoA-I, α1-AT and inflammation in blood stasis syndrome of coronary heart disease,” Journal of Beijing University of Traditional Chinese Medicine, vol. 33, no. 4, pp. 253–256, 2010. View at Google Scholar
  25. Y. Lv, Y.-P. Wang, W.-J. Li, and L. Zhang, “Clinical researches that the serum NO ET IL-6 varieties of chronic renal failure patients with blood stasis symptom and effect of Lei's Danshen tablets,” Chinese Traditional Patent Medicine, vol. 28, no. 1, pp. 63–67, 2006. View at Google Scholar